Citation: | Yan Hui, Wu Furong, Ji Peng, et al. Evaluation of the predictive ability of individualized drug administration adjuvant decision-making system JPKD for tacrolimus blood concentration in kidney transplant recipients[J]. ORGAN TRANSPLANTATION. doi: 10.3969/j.issn.1674-7445.2024011 |
[1] |
中华医学会器官移植学分会. 器官移植免疫抑制剂临床应用技术规范(2019版)[J]. 器官移植, 2019, 10(3): 213-226. DOI: 10.3969/j.issn.1674-7445.2019.03.001.
Organ Transplantation Society of Chinese Medical Association. Technical specifications for clinical application of immunosuppressants in organ transplantation (2019)[J]. Organ Transplant, 2019, 10(3): 213-226. DOI: 10.3969/j.issn.1674-7445.2019.03.001.
|
[2] |
WANG XH, SHAO K, AN HM, et al. The pharmacokinetics of tacrolimus in peripheral blood mononuclear cells and limited sampling strategy for estimation of exposure in renal transplant recipients[J]. Eur J Clin Pharmacol, 2022, 78(8): 1261-1272. DOI: 10.1007/s00228-021-03215-9.
|
[3] |
MORAIS MC, SOARES ME, COSTA G, et al. Impact of tacrolimus intra-patient variability in adverse outcomes after organ transplantation[J]. World J Transplant, 2023, 13(5): 254-263. DOI: 10.5500/wjt.v13.i5.254.
|
[4] |
CHEN D, LU H, SUI W, et al. Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients[J]. Pharmacogenomics J, 2021, 21(3): 376-389. DOI: 10.1038/s41397-021-00216-w.
|
[5] |
陈文倩, 张雷, 张弋, 等. 实体器官移植他克莫司个体化治疗专家共识[J]. 中国医院用药评价与分析, 2021, 21(12): 1409-1424. DOI: 10.14009/j.issn.1672-2124.2021.12.001.
CHEN WQ, ZHANG L, ZHANG Y, et al. Expert consensus on individual treatment of tacrolimusin solid organ transplantation[J]. Eval Anal Drug-Use Hosp China, 2021, 21(12): 1409-1424. DOI: 10.14009/j.issn.1672-2124.2021.12.001.
|
[6] |
WOLF U. A drug safety concept (I) to avoid polypharmacy risks in transplantation by individual pharmacotherapy management in therapeutic drug monitoring of immunosuppressants[J]. Pharmaceutics, 2023, 15(9): 2300. DOI: 10.3390/pharmaceutics15092300.
|
[7] |
广东省药学会. 肾移植患者免疫抑制剂长期管理医药专家共识[J]. 今日药学, 2022, 32(11): 801-816. DOI: 10.12048/j.issn.1674-229X.2022.11.001.
Guangdong Pharmaceutical Society. Expert consensus on long-term management of immunosuppressants in renal transplant recipients[J]. Pharm Today, 2022, 32(11): 801-816. DOI: 10.12048/j.issn.1674-229X.2022.11.001.
|
[8] |
ETTE EI, WILLIAMS PJ. Population pharmacokinetics I: background, concepts, and models[J]. Ann Pharmacother, 2004, 38(10): 1702-1706. DOI: 10.1345/aph.1D374.
|
[9] |
DUFFULL SB, WRIGHT DF. What do we learn from repeated population analyses?[J]. Br J Clin Pharmacol, 2015, 79(1): 40-47. DOI: 10.1111/bcp.12233.
|
[10] |
GU JQ, GUO YP, JIAO Z, et al. How to handle delayed or missed doses: a population pharmacokinetic perspective[J]. Eur J Drug Metab Pharmacokinet, 2020, 45(2): 163-172. DOI: 10.1007/s13318-019-00598-0.
|
[11] |
TENG F, ZHANG W, WANG W, et al. Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients[J]. Biopharm Drug Dispos, 2022, 43(2): 76-85. DOI: 10.1002/bdd.2311.
|
[12] |
PASCHIER A, DESTERE A, MONCHAUD C, et al. Tacrolimus population pharmacokinetics in adult heart transplant patients[J]. Br J Clin Pharmacol, 2023, 89(12): 3584-3595. DOI: 10.1111/bcp.15857.
|
[13] |
KAMP J, ZWART TC, MEZIYERH S, et al. Meltdose tacrolimus population pharmacokinetics and limited sampling strategy evaluation in elderly kidney transplant recipients[J]. Pharmaceutics, 2023, 16(1): 17. DOI: 10.3390/pharmaceutics16010017.
|
[14] |
DU Y, SONG W, XIONG X, et al. Population pharmacokinetics and dosage optimisation of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients[J]. Xenobiotica, 2022, 52(3): 274-283. DOI: 10.1080/00498254.2022.2073851.
|
[15] |
CAI X, SONG H, JIAO Z, et al. Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients[J]. Eur J Pharm Sci, 2020, 152: 105448. DOI: 10.1016/j.ejps.2020.105448.
|
[16] |
CHENG Y, CHEN J, LIN X, et al. Population pharmacokinetic analysis for model-based therapeutic drug monitoring of tacrolimus in Chinese Han heart transplant patients[J]. Eur J Drug Metab Pharmacokinet, 2023, 48(1): 89-100. DOI: 10.1007/s13318-022-00807-3.
|
[17] |
JING Y, KONG Y, HOU X, et al. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients[J]. J Clin Pharm Ther, 2021, 46(4): 1117-1128. DOI: 10.1111/jcpt.13407.
|
[18] |
BRUNET M, VAN GELDER T, ÅSBERG A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report[J]. Ther Drug Monit, 2019, 41(3): 261-307. DOI: 10.1097/FTD.0000000000 000640.
|
[19] |
韩璐, 徐方敏, 张晓珊, 等. 个体化给药辅助决策系统Smart Dose、PharmVan与JPKD对万古霉素血药浓度预测能力的评价[J]. 中华危重病急救医学, 2021, 33(3): 263-268. DOI: 10.3760/cma.j.cn121430-20201016- 00674.
HAN L, XU FM, ZHANG XS, et al. Predictive performance of Smart Dose, PharmVan and JPKD on Vancomycin plasma concentration[J]. Chin Crit Care Med, 2021, 33(3): 263-268. DOI: 10.3760/cma.j.cn121430-20201016-00674.
|
[20] |
刘雪姣, 周青, 赵宇蕾, 等. 万古霉素个体化给药辅助决策系统在重症患者中的应用[J]. 中国医院药学杂志, 2020, 40(20): 2143-2146,2157. DOI: 10.13286/j.1001-5213.2020.20.10.
LIU XJ, ZHOU Q, ZHAO YL, et al. Application of vancomycin individualized dosage auxiliary system in ICU patients[J]. Chin J Hosp Pharm, 2020, 40(20): 2143-2146,2157. DOI: 10.13286/j.1001-5213.2020.20.10.
|
[21] |
何娟, 杨婉花. 基于群体药动学的万古霉素个体化给药模式的建立和临床应用[J]. 中国临床药学杂志, 2015, 24(1): 27-31.
HE J, YANG WH. Establishment of the individualized drug delivery model of vancomycin for infected patients based on population pharmacokinetics and its clinical application[J]. Chin J Clin Pharm, 2015, 24(1): 27-31.
|
[22] |
张海波, 吴雨璇, 孔令文, 等. 个体化给药辅助软件应用于万古霉素个体化给药的效果评价[J]. 中国药物滥用防治杂志, 2022, 28(9): 1225-1228. DOI: 10.15900/j.cnki.zylf1995.2022.09.012.
ZHANG HB, WU YX, KONG LW, et al. Application of personalized drug administration assistant software in vancomycin personalized drug administration[J]. Chin J Drug Abuse Prev Treat, 2022, 28(9): 1225-1228. DOI: 10.15900/j.cnki.zylf1995.2022.09.012.
|
[23] |
仇晓威. 群体药动学方法调整患者万古霉素使用效果的分析[J]. 医学信息, 2023, 36(22): 97-100. DOI: 10.3969/j.issn.1006-1959.2023.22.021.
QIU XW. Analysis of the effect of population pharmacokinetic method on adjusting the use of vancomycin in patients[J]. Med Inform, 2023, 36(22): 97-100. DOI: 10.3969/j.issn.1006-1959.2023.22.021.
|
[24] |
杨浩, 熊雄, 刘长江. 骨科术后患者万古霉素峰谷浓度的影响因素及群体药动学预测比较[J]. 中国医院药学杂志, 2023, 43(24): 2722-2728. DOI: 10.13286/j.1001-5213.2023.24.02.
YANG H, XIONG X, LIU CJ. Factors influencing peak and trough vancomycin concentrations in postoperative orthopaedic patients and its comparative population pharmacokinetic prediction[J]. Chin Jo Hosp Pharm, 2023, 43(24): 2722-2728. DOI: 10.13286/j.1001-5213.2023.24.02.
|
[25] |
ZHANG HX, SHENG CC, LIU LS, et al. Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus[J]. Br J Clin Pharmacol, 2019, 85(4): 746-761. DOI: 10.1111/bcp.13850.
|
[26] |
KIRUBAKARAN R, STOCKER SL, HENNIG S, et al. Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review[J]. Clin Pharmacokinet, 2020, 59(11): 1357-1392. DOI: 10.1007/s40262-020-00922-x.
|
[27] |
ASBERG A, FALCK P, UNDSET LH, et al. Computer-assisted cyclosporine dosing performs better than traditional dosing in renal transplant recipients: results of a pilot study[J]. Ther Drug Monit, 2010, 32(2): 152-158. DOI: 10.1097/FTD.0b013e3181d3f822.
|
[28] |
FAELENS R, LUYCKX N, KUYPERS D, et al. Predicting model-informed precision dosing: a test-case in tacrolimus dose adaptation for kidney transplant recipients[J]. CPT Pharmacometrics Syst Pharmacol, 2022, 11(3): 348-361. DOI: 10.1002/psp4.12758.
|
[29] |
刘晓芹, 焦正, 高玉成, 等. 个体化给药辅助决策系统研究与应用进展[J]. 中国药学杂志, 2019, 54(1): 1-8. DOI: 10.11669/cpj.2019.01.001.
LIU XQ, QIAO Z, GAO YC, et al. Progress in development and application of decision-making systems for individualized dosing[J]. Chin Pharm J, 2019, 54(1): 1-8. DOI: 10.11669/cpj.2019.01.001.
|
[30] |
陆晓玲, 王雨萍, 邵琨, 等. CYP3A5、ABCB1基因多态性对中国肾移植患者服用他克莫司剂量和血药浓度的影响[J]. 药学与临床研究, 2023, 31(6): 481-485.
LU XL, WANG YP, SHAO K, et al. Effects of CYP3A5 and ABCB1 gene polymorphisms on dosages and blood concentrations of tacrolimus in chinese kidney transplant patients[J]. Pharm Clin Res, 2023, 31(6): 481-485.
|
[31] |
CHAUHAN PM, HEMANI RJ, SOLANKI ND, et al. A systematic review and meta-analysis recite the efficacy of Tacrolimus treatment in renal transplant patients in association with genetic variants of CYP3A5 gene[J]. Am J Clin Exp Urol, 2023, 11(4): 275-292.
|
[32] |
LU H, JIANG H, YANG S, et al. Trans-eQTLs of the CYP3A4 and CYP3A5 associated with tacrolimus trough blood concentration in Chinese renal transplant patients[J]. Biomed Pharmacother, 2022, 145: 112407. DOI: 10.1016/j.biopha.2021.112407.
|
[33] |
HANNACHI I, CHADLI Z, KERKENI E, et al. Influence of CYP3A polymorphisms on tacrolimus pharmacokinetics in kidney transplant recipients[J]. Pharmacogenomics J, 2021, 21(1): 69-77. DOI: 10.1038/s41397-020-00179-4.
|
[34] |
YU M, LIU M, ZHANG W, et al. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation[J]. Curr Drug Metab, 2018, 19(6): 513-522. DOI: 10.2174/138920021966618012915 1948.
|
[35] |
CAI XJ, LI RD, LI JH, et al. Prospective population pharmacokinetic study of tacrolimus in adult recipients early after liver transplantation: a comparison of Michaelis-Menten and theory-based pharmacokinetic models[J]. Front Pharmacol, 2022, 13: 1031969. DOI: 10.3389/fphar.2022.1031969.
|
[36] |
FRANKEN LG, FRANCKE MI, ANDREWS LM, et al. A population pharmacokinetic model of whole-blood and intracellular tacrolimus in kidney transplant recipients[J]. Eur J Drug Metab Pharmacokinet, 2022, 47(4): 523-535. DOI: 10.1007/s13318-022-00767-8.
|
[37] |
KHAMLEK K, KOMENKUL V, SRIBOONRUANG T, et al. Population pharmacokinetic models of tacrolimus in paediatric solid organ transplant recipients: a systematic review[J]. Br J Clin Pharmacol, 2024, 90(2): 406-426. DOI: 10.1111/bcp.15909.
|
[38] |
ZAHIR H, MCLACHLAN AJ, NELSON A, et al. Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients[J]. Ther Drug Monit, 2005, 27(4): 422-430. DOI: 10.1097/01.ftd.0000170029.36573.a0.
|